NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
Institut Claudius Regaud
Sichuan Baili Pharmaceutical Co., Ltd.
BioNTech SE
Peking University Cancer Hospital & Institute
ImmunoGenesis
Beijing Biostar Pharmaceuticals Co., Ltd.
Genentech, Inc.
Jiangsu HengRui Medicine Co., Ltd.
InxMed (Shanghai) Co., Ltd.
3D Medicines
InxMed (Shanghai) Co., Ltd.
TCRCure Biopharma Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.